ZLZhen Li

Zhen Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhen Li has a total of 115 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Data from Targeting RET Kinase in Neuroendocrine Prostate Cancer

    by Halena R. VanDeusen, Johnny R. Ramroop, Katherine L. Morel, Song Yi Bae, Anjali V. Sheahan, Zoi Sychev, Nathan A. Lau, Larry C. Cheng, Victor M. Tan, Zhen Li, et al.

    The increased treatment of metastatic castration-resistant prostate cancer (mCRPC) with second-generation antiandrogen therapies (ADT) has coincided with a greater incidence of lethal, aggressive variant prostate cancer (AVPC) tumors that have lost dependence on androgen receptor (AR) signaling. These AR-independent tumors may also transdifferentiate to express neuroendocrine lineage markers and are termed neuroendocrine prostate cancer (NEPC). Recent evidence suggests kinase signaling may be an important driver of NEPC. To identify targetable kinases in NEPC, we performed global phosphoproteomics comparing several AR-independent to AR-dependent prostate cancer cell lines and identified multiple altered signaling pathways, including enrichment of RET kinase activity in the AR-independent cell lines. Clinical NEPC patient samples and NEPC patient-derived xenografts displayed upregulated RET transcript and RET pathway activity. Genetic knockdown or pharmacologic inhibition of RET kinase in multiple mouse and human models of NEPC dramatically reduced tumor growth and decreased cell viability. Our results suggest that targeting RET in NEPC tumors with high RET expression could be an effective treatment option. Currently, there are limited treatment options for patients with aggressive neuroendocrine prostate cancer and none are curative.Implications:Identification of aberrantly expressed RET kinase as a driver of tumor growth in multiple models of NEPC provides a significant rationale for testing the clinical application of RET inhibitors in patients with AVPC.

  • Open Access

    Supplementary Tables 1-8 from Targeting RET Kinase in Neuroendocrine Prostate Cancer

    by Halena R. VanDeusen, Johnny R. Ramroop, Katherine L. Morel, Song Yi Bae, Anjali V. Sheahan, Zoi Sychev, Nathan A. Lau, Larry C. Cheng, Victor M. Tan, Zhen Li, et al.

    Supplemental Table 1: Known genetic mutations of genes commonly mutated in mCRPC in cell lines used in phosphoproteome analysis Supplemental Table 2: Phospho-Serine/Threonine proteome of Prostate Cancer Adenocarcinoma and Aggressive Variant Prostate Cancer Cell Lines Supplemental Table 3: Phospho-Tyrosine proteome of Prostate Cancer Adenocarcinoma and Aggressive Variant Prostate Cancer Cell Lines Supplemental Table 4: Kinase Substrate Enrichment Analysis results from phospho-serine/threonine proteome dataset Supplemental Table 5: Kinase Substrate Enrichment Analysis results from phospho-tyrosine proteome dataset Supplemental Table 6: Phospho-Serine/Threonine proteome of Adenocarcinoma or Small cell/Mixed phenotype mCRPC patient samples Supplemental Table 7. Spearman's Correlation Between the Dependency Ranks of RET and Other Genes in Prostate Cancer Cell Lines Supplemental Table 8. RET Dependency Scores of Cancer Cell Lines

  • Open Access

    Supplementary Methods, Supplementary Figures 1-6 from Targeting RET Kinase in Neuroendocrine Prostate Cancer

    by Halena R. VanDeusen, Johnny R. Ramroop, Katherine L. Morel, Song Yi Bae, Anjali V. Sheahan, Zoi Sychev, Nathan A. Lau, Larry C. Cheng, Victor M. Tan, Zhen Li, et al.

    Supplemental Figure 1. RET expression is higher in prostate cancer lines that have lost androgen receptor signaling Supplemental Figure 2. RET gene expression is higher in patient samples with pure/mixed small cell phenotype or primary NEPC and correlates with other neuroendocrine markers. Supplemental Figure 3. Knockdown of RET kinase in PC3 cells shows a modest reduction in cellular proliferation. Supplemental Figure 4. Prostate cancer cell lines show variable sensitivity to RET inhibitor treatment. Supplemental Figure 5. Organoids derived from PTEN-/- and Rb-/- prostate cells model multiple aspects of NEPC including resistance to enzalutamide treatment. Supplemental Figure 6. A higher dose replicate of AD80 treatment of NCI-H660 xenograft tumors shows a similar effect of restricting tumor growth.

  • Open Access

    Data from Targeting RET Kinase in Neuroendocrine Prostate Cancer

    by Halena R. VanDeusen, Johnny R. Ramroop, Katherine L. Morel, Song Yi Bae, Anjali V. Sheahan, Zoi Sychev, Nathan A. Lau, Larry C. Cheng, Victor M. Tan, Zhen Li, et al.

    The increased treatment of metastatic castration-resistant prostate cancer (mCRPC) with second-generation antiandrogen therapies (ADT) has coincided with a greater incidence of lethal, aggressive variant prostate cancer (AVPC) tumors that have lost dependence on androgen receptor (AR) signaling. These AR-independent tumors may also transdifferentiate to express neuroendocrine lineage markers and are termed neuroendocrine prostate cancer (NEPC). Recent evidence suggests kinase signaling may be an important driver of NEPC. To identify targetable kinases in NEPC, we performed global phosphoproteomics comparing several AR-independent to AR-dependent prostate cancer cell lines and identified multiple altered signaling pathways, including enrichment of RET kinase activity in the AR-independent cell lines. Clinical NEPC patient samples and NEPC patient-derived xenografts displayed upregulated RET transcript and RET pathway activity. Genetic knockdown or pharmacologic inhibition of RET kinase in multiple mouse and human models of NEPC dramatically reduced tumor growth and decreased cell viability. Our results suggest that targeting RET in NEPC tumors with high RET expression could be an effective treatment option. Currently, there are limited treatment options for patients with aggressive neuroendocrine prostate cancer and none are curative.Implications:Identification of aberrantly expressed RET kinase as a driver of tumor growth in multiple models of NEPC provides a significant rationale for testing the clinical application of RET inhibitors in patients with AVPC.

  • Open Access

    Supplementary Methods, Supplementary Figures 1-6 from Targeting RET Kinase in Neuroendocrine Prostate Cancer

    by Halena R. VanDeusen, Johnny R. Ramroop, Katherine L. Morel, Song Yi Bae, Anjali V. Sheahan, Zoi Sychev, Nathan A. Lau, Larry C. Cheng, Victor M. Tan, Zhen Li, et al.

    Supplemental Figure 1. RET expression is higher in prostate cancer lines that have lost androgen receptor signaling Supplemental Figure 2. RET gene expression is higher in patient samples with pure/mixed small cell phenotype or primary NEPC and correlates with other neuroendocrine markers. Supplemental Figure 3. Knockdown of RET kinase in PC3 cells shows a modest reduction in cellular proliferation. Supplemental Figure 4. Prostate cancer cell lines show variable sensitivity to RET inhibitor treatment. Supplemental Figure 5. Organoids derived from PTEN-/- and Rb-/- prostate cells model multiple aspects of NEPC including resistance to enzalutamide treatment. Supplemental Figure 6. A higher dose replicate of AD80 treatment of NCI-H660 xenograft tumors shows a similar effect of restricting tumor growth.

  • Open Access

    Supplementary Tables 1-8 from Targeting RET Kinase in Neuroendocrine Prostate Cancer

    by Halena R. VanDeusen, Johnny R. Ramroop, Katherine L. Morel, Song Yi Bae, Anjali V. Sheahan, Zoi Sychev, Nathan A. Lau, Larry C. Cheng, Victor M. Tan, Zhen Li, et al.

    Supplemental Table 1: Known genetic mutations of genes commonly mutated in mCRPC in cell lines used in phosphoproteome analysis Supplemental Table 2: Phospho-Serine/Threonine proteome of Prostate Cancer Adenocarcinoma and Aggressive Variant Prostate Cancer Cell Lines Supplemental Table 3: Phospho-Tyrosine proteome of Prostate Cancer Adenocarcinoma and Aggressive Variant Prostate Cancer Cell Lines Supplemental Table 4: Kinase Substrate Enrichment Analysis results from phospho-serine/threonine proteome dataset Supplemental Table 5: Kinase Substrate Enrichment Analysis results from phospho-tyrosine proteome dataset Supplemental Table 6: Phospho-Serine/Threonine proteome of Adenocarcinoma or Small cell/Mixed phenotype mCRPC patient samples Supplemental Table 7. Spearman's Correlation Between the Dependency Ranks of RET and Other Genes in Prostate Cancer Cell Lines Supplemental Table 8. RET Dependency Scores of Cancer Cell Lines

  • A Global Phase‐Modulation Mechanism for Flat‐Lens Design

    by Xin Zhang, Yanwen Hu, Xiliang Zhang, Siqi Zhu, Hao Yin, Zhen Li, Zhenqiang Chen, Shenhe Fu

    Flat lens also known as metasurface lens is drawing considerable attention nowadays. Thus far, the metasurface lens has been achieved by engineering local phase profile in deep subwavelength scale according to resonant or non‐resonant (or both) responses of nanoscatters to light. Such local phase mappings require precise control over each nanoscatter. In addition, there is currently no metasurface lens that exhibits multiple functionalities. Here, a novel working mechanism, named as a global phase‐modulation mechanism, for the flat‐lens design is demonstrated. To illustrate this concept, a binary amplitude‐only hologram is introduced, resulted from an interference between an angular cosine wave and a spherical wave. The resultant flat lens can be made extremely thin (60 nm) and is comprised of spatially shaped apertures. Such a technique allows to globally manipulate the diffractive wave vectors in the reciprocal space. Multiple focusing performances with a single flat lens are demonstrated under different illumination beams including the plane‐wave beam, vortex beam, and vector beam. In addition to imaging, the flat lens is able to Fourier transforming a complex self‐accelerating Airy beam, which was not considered before. The presented global mechanism facilitates new capabilities and holds for multifunctional flat lens, with potential applications in areas such as imaging and optical information processing.


  • Multiphoton microscopy for monitoring the occurrence, metastasis and therapy of breast cancer

    by Yulan Liu, Yu Yi, Zhen Li, Lianhuang Li, Zhenlin Zhan, Jianxin Chen, Liqin Zheng

    Worldwide, the most common malignancy in women is breast cancer. At present, the gold standard for breast cancer diagnosis, namely pathological analysis, cannot reach the subcellular level, and is unable to provide more physiological information. Multiphoton microscopy (MPM) has its unique advantages, such as label‐free detection, high resolution, low damage, deep imaging depth, low photobleaching and phototoxicity, and so on, which make up for the deficiences of traditional methods. This review mainly introduces the principle of MPM and its applications in breast diseases, especially in monitoring the occurrence, progression, metastasis, and therapy response of tumor. At the same time, the performance and progress of MPM combined with nanomaterials in breast cancer treatment are summarized. Finally, we propose the clinical challenges and future research directions of MPM.


  • Open Access

    MSK1 downregulation is involved in inflammatory responses following subarachnoid hemorrhage in rats

    by Bo Ning, Zhen Li, Lei Ning, Jun Wu, Xin Chen, Pengjun Jiang, Fuxin Lin, Bing Zhao

    Subarachnoid hemorrhage (SAH) is a life‑threatening neurological disease. Recently, inflammatory factors have been confirmed to be responsible for the brain damage associated with SAH. Therefore, studying the post‑SAH inflammatory reaction may clarify the mechanism of SAH. Mitogen and stress‑activated protein kinase 1 (MSK1) causes the phosphorylation of NF‑κB and regulates the activity of pro‑inflammatory transcription factors. The present study aimed to identify the potential role of MSK1 in inflammation and brain damage development following SAH. A cisterna magna blood injection model was established in Sprague‑Dawley rats. Hematoxylin and eosin staining, reverse transcription‑quantitative polymerase chain reaction assays and double immunofluorescence staining were used to analyze the role of MSK1, IL‑1β and TNF‑α in the inflammatory process after SAH. In a model of lipopolysaccharide‑induced astrocyte inflammation, the effect of overexpressing MSK1 overexpression was analyzed by western blot analysis. The results demonstrated that MSK1 expression were negatively correlated with TNF‑α and IL‑1β expression levels, and reached peak levels 2 days after TNF‑α and IL‑1β. The double immunofluorescence staining results showed that the expression of MSK1 was in the same plane of view as TNF‑α and IL‑1β in the brain cortex. Furthermore, the in vitro studies indicated that the overexpression of MSK1 inhibited the expression of TNF‑α and IL‑1β following LPS challenge. These results imply that MSK1 may be involved in the inflammatory reaction following SAH, and may potentially serve as a negative regulator of inflammation.


  • Effect of miR-210 on Proliferation and Migration of Pancreatic Cancer Cells Through Regulating Runx3 Level

    by Wanggang Xu, Yingmin Kuang, Dan Wang, Zhen Li, Renpin Xia

    MiR-210 is closely related to the occurrence of pancreatic cancer. In addition, Runx3 is a tumor suppressor gene and inhibits tumorigenesis. However, miR-210?s effect on Runx3 level is unclear. Therefore, Our study explored miR-210?s effect on the proliferation and migration of pancreatic cancer cells. PANC-1 cell line was transfected with miR-210 Mimics or miR-210 Mimic+pFBD-Runx3 plasmids followed by analysis of miR-210 and Runx3 level by qRT-PCR, targeting relationship by the dual fluorescein reporter assay, Runx3 and Tubulin protein expression by Western blot, cell proliferation by MTT assay and cell migration by Transwell assay. Compared with normal tissue, miR-210 was significantly upregulated in pancreatic cancer tissue (P < 0.01), while Runx3 mRNA was significantly downregulated (P < 0.01). Runx3 was a target protein of miR-210. miR-210 Mimics transfection significantly reduced Runx3 level and increased cell proliferation, which was significantly reduced in the miR-210 Mimic+pFBD-Runx3 group. miR-210 Mimics significantly promote cell migration and the addition of Runx3 prevented miR-210 Mimics-induced cell migration. miR-210 binds to the 3′-UTR region of Runx3 mRNA, reduces Runx3 expression, and promotes cell proliferation and migration. Increased Runx3 can inhibit miR-210?s effect on pancreatic cancer cells.